U.S. Markets open in 3 hrs 13 mins

Orexigen Therapeutics, Inc. (OREX)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
2.98-0.10 (-3.25%)
At close: 4:00PM EDT
People also watch
VVUSARNAKERXMNKDACHN
  • To all those who are losing money in this, just keep in mind it will be significantly profitable in 2018. Just hang in there! It is the best in class and may even get approval for cardiovascular benefits.
  • IGXT (MC $46 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $46 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL

    Intelgenx (IGXT)

    MarketCap $46 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.70

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • The trading setup for OREX looks very enticing. if you guys have questions you should ask AWE.some.STOCKS. They often respond to my emails which is helpful.
  • any new catalysts for this stock in next month?
  • Noooooooo Voluuuuume ..... bummer Monday
  • Nothing special with OREX. The whole sector was in favor yesterday
  • Wow. looked at this company for first time in two years. Zero prospects for anything good. and a self-dealing management.
  • OREX is up 8.60% to 3.03
  • Yahoo to buy OREX for $20
  • WOW big volume today.
  • OREX -- Valeant - buy OREX for $12.00 ??? my wish ------
  • Crickets.....
  • Well this price action is sucking hard!
  • Do you think this thing is done selling? Showing us a buy signal now on OREX? if you guys have questions you should ask awesome-STOCKS. They often respond to my emails which is helpful.
  • has anyone checked out GBTC???? Is that not the craziest thing you have ever seen?
  • It is a wise father that knows his own child.http://dataunion.tistory.com/9054

    Orexigen Therapeutics NASDAQ $OREX Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.5 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • (AXSM) Market Cap $92 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $92 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $92 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$4.10

    Shares Out: 23.5 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation May
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjcwNTc4fENoaWxkSUQ9Mzc3ODc0fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3......Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3.......No approved medication = unmet medical need. 2M patients in the U.S.

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status).......No approved drug = high unmet need. 80,000 new cases per year in the U.S.

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track).........7M patients in the U.S.

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 ......1.6M patients in the U.S.

  • long TGTX
  • If you are looking to scalp $3.05 area is where it will go back up to about $3.75 ish
  • Guys how are the earnings ?